Mirum’s Livmarli Now FDA Approved in Tablet Formulation

FOSTER CITY, Calif.–(BUSINESS WIRE) April 14, 2025 — Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Livmarli (maralixibat) for the treatment of…Original Article